Details of the Drug Reposition

General Information of This Drug (ID: DMZHUO5)

Drug Name
Phenylephrine   DMZHUO5
Synonyms
Cyclomydril; Dilatair; Dionephrine; Doktors; Duration; Fenilefrina; Isophrim; Isophrin; Mesaton; Mesatone; Mesatonum; Metaoxedrin; Metaoxedrine; Metaoxedrinum; Metasympatol; Metasynephrine; Metsatonum; Mezaton; Mydfrin; Neofrin; Neosynephrine; Nostril; Ocugestrin; Phenoptic; Phenylephrinum; Spersaphrine; Visadron; Alcon Efrin; Isopto Frin; Minims Phenylephrine; Nostril Spray Pump; Nostril Spray Pump Mild; Phenylephrine Minims; Prefrin Liquifilm; Relief Eye Drops for Red Eyes; Alconefrin Nasal Drops 12; Alconefrin Nasal Drops 25; Alconefrin Nasal Drops 50; Alconefrin Nasal Spray 25; Ah-Chew; Ak-dilate; Ak-nefrin; Fenilefrina [INN-Spanish]; I-Phrine; L-Phenylephedrine; L-Phenylephrine; M-Methylaminoethanolphenol; M-Oxedrine; M-Sympathol; M-Sympatol; M-Synephrine; Mydfrin (TN); Neo-Synephrine; Neo-Synephrine Nasal Drops; Neo-Synephrine Nasal Jelly; Neo-Synephrine Nasal Spray; Ocu-Phrin Sterile Eye Drops; Phenylephrine (INN); Phenylephrine Minims (TN); Phenylephrine [INN:BAN]; Phenylephrinum [INN-Latin]; R(-)-Phenylephrine; L-(3-Hydroxyphenyl)-N-methylethanolamine; L-1-(m-Hydroxyphenyl)-2-methylaminoethanol; L-m-Hydroxy-alpha-((methylamino)methyl)benzyl alcohol; L-alpha-Hydroxy-beta-methylamino-3-hydroxy-L-ethylbenzene; Tannins, compds. with (R)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol; Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)-(9CI); (-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol; (R)-2-Hydroxy-2-(3-hydroxyphenyl)-N-methylethylamine; (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol; 3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol
Therapeutic Class
Ophthalmologicals
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
11 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Ophthalmic graves disease DISDCYDF 5A02.0 Approved [1]
Headache DISK4TGU 8A80-8A84 Approved [2]
Arrhythmia DISFF2NI BC9Z Approved [2]
Common cold DIS3MADM CA00 Approved [2]
Vasomotor/allergic rhinitis DISHSTQ0 CA08 Approved [2]
Proctitis DIS3K8ZM DB33.Z Approved [2]
Rhinitis DISKLMN7 FA20 Approved [2]
Mydriasis DISG7YFO LA11.62 Approved [2]
Cough DIS51FA4 MD12 Approved [2]
Fecal incontinence DIS9TWSG ME07 Approved [3]
Fever DISJGEAQ MG26 Approved [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 Indications(s)
1 Withdrawn Indication(s)
Indication Name Indication ID ICD-11 Status REF
Allergic conjunctivitis DISZ5ZJN 9A60.02 Withdrawn [4]
------------------------------------------------------------------------------------
2 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Paroxysmal extreme pain disorder DISNHO6B N.A. Discontinued in Phase 2 [5]
Hemorrhoids DISQ5G6G DB60 Discontinued in Phase 2 [6]
------------------------------------------------------------------------------------

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 485).
2 Isoproterenol FDA Label
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019494)
4 Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small Cell Lung Cancer
5 Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
6 ClinicalTrials.gov (NCT00826449) Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)